If there is one disease for which patients have experienced a significant improvement in the cure rate over the past 10 years, it is diffuse large B-cell lymphoma (DLBCL).
Christian Gisselbrecht, MD
Advertisement
Articles by Christian Gisselbrecht, MD
Advertisement
Latest Updated Articles
- Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?
Published: May 15th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
4
Classifying High-Risk Patients With NDMM
5
